drugset
drugset / Trial / NCT04412564

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

NCT04412564 ↗

Phase 2 Unknown 200 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with advanced malignant tumor.

Timeline

Start
2020-08-05
Primary completion
2021-03-31
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Unecritinib Small molecule 300 mg Oral

Indications

cancer